Status:

RECRUITING

Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction

Lead Sponsor:

Aswan University Hospital

Collaborating Sponsors:

Aswan University

Cairo University

Conditions:

Erectile Dysfunction With Diabetes Mellitus

Eligibility:

MALE

21+ years

Phase:

PHASE2

PHASE3

Brief Summary

Study is aiming to evaluate safety, efficacy and durability of intracavernosal injection (ICI) of Botulinum toxin A plus oral tadalafil in controlled diabetic men with refractory Erectile Dysfunction.

Detailed Description

Total of (32) male patients will be included in this study and will be recruited from the Andrology, Sexology \& STDs outpatient clinics- Faculty of medicine -Cairo and Aswan Universities. All those p...

Eligibility Criteria

Inclusion

  • Adult controlled diabetic married men who proved to be vasculogenic ED by Penile Duplex.
  • Men who had shown an insufficient response for at least 3 months to the registered PDE5-Is at the highest approved dose, either on-demand or daily, or to PGE1 ICIs.
  • Severe erectile dysfunction (erection hardness score ≤ E3 after intracavernosal injection of PGE-1).

Exclusion

  • Men who had cardiovascular disease interfering with sexual activity.
  • Men with history of an unstable psychiatric conditions
  • Presence of penile anatomical abnormalities that would significantly impair erectile function.
  • History of spinal or pelvic radical surgery.

Key Trial Info

Start Date :

August 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT06583590

Start Date

August 1 2024

End Date

December 1 2025

Last Update

December 3 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Aswan University-Faculty of Medicine

Aswān, Aswan Governorate, Egypt, 81528